Tags Posts tagged with "cbd"

cbd

0 2866

CBD is well-known for its health benefits, especially in treating rare seizure disorders. There are other reasons people try CBD products, also. A neurologist and psychopharmacology researcher, Dr. Ethan Russo, notes in a study that the therapeutic effects of CBD are broad, including: analgesic, anti-inflammatory, antiemetic, antioxidant, anti-psychotic, anti-anxiety, anti-convulsant and cytotoxic in certain cancer cells. Typically, CBD products are primarily made from the concentrated extract of the flowers, leaves and possibly stalks of marijuana or hemp. Most CBD products are either oil-based tinctures or capsules that are consumed orally, or topicals applied to the skin. However, there is a growing variety of other products containing CBD, including those for pets.

To find out if CBD would show on a urine drug test, we consulted employment drug testing expert Barry Sample, who is the director of science and technology for Quest Diagnostics. Sample stated, “If the product contains only CBD and has had the THC removed, then an individual being tested would not be expected to test positive for marijuana or marijuana metabolite.” We contacted cannabis health and science researcher, Paul Armentano. Armentano stated, “Not unless those products also contain quantities of THC. Drug tests screen for either THC or the carboxy-THC metabolite, not for CBD.”

Both experts agree; as long as there is no THC in the CBD products, then a urine test would not test positive for THC. There may be minute amounts of THC in CBD products. An aspect in cannabinoid compounds that aids efficacy is the entourage effect. Coined by venerable Israeli cannabis researcher Raphael Mechoulam in 1999, the entourage effect is the belief that the compounds in marijuana work better together than if the compounds are isolated. CBD products, in addition to the CBD cannabinoid, may contain additional cannabis compounds, including THC, to purportedly increase the effectiveness of the product.

0 1678

Physicians will not prescribe marijuana to treat autism in children because no information exists to support such a course of therapy . However, the research does not exist because of medical establishment worries about marijuana testing, with its many active compounds seen as conceivably uncontrollable variables, on children. In the absence of practical information, however, is a growing body of anecdotal proof that marijuana is making autistic children healthier and happier. Some physicians are listening.

Doctor Daniele Piomelli, one of the world’s top neuroscientists and endocannabinoid researchers stated, “Anecdotes should not be dismissed.” The University of California-Irvine faculty member will not consider prescribing marijuana at this time, but is aware of the increasing desire for it. Piomelli continued, “An anecdote is a pointer. It’s something that suggests something needs to be either proven or disproven.”

One scientist attempting to do just that is Doctor Giovanni Martinez, a clinical psychologist in Puerto Rico. His alternative treatment includes his creation of SURF4DEM, a foundation that introduces children and families affected by autism to the therapeutic benefits of surfing. Martinez is studying the therapeutic possibilities of treating children who have autism with CBD oil, and reports positive results. He recounted one particular case in which a child he treated spoke his first words after receiving a twice-daily spray of hemp oil. After three weeks, the child went from being non-verbal to developing considerable language skills.

Martinez stated, “initially the child would become so frustrated with his inability to communicate, he would would act out and injure himself. But, now that he can express himself, he laughs and enjoys life.” Martinez continued, “It’s incredible to see a child go from being non-communicative to achieving a significant improvement in quality of life, for both the child and his family.”

0 3796

Since growing hemp has been illegal for almost a full century, researchers have been unable to learn all the benefits associated with it. Currently, most states have an active hemp industry or have authorized hemp research.

Hemp is a distinct variety of the cannabis plant but it is not the same as marijuana. Although hemp is commonly associated with marijuana, it should not be.

Industrial hemp and marijuana are two completely different plants, inside and out. Hemp contains a very small amount (less than 1%) of tetrahydrocannabinol (THC), the primary psychoactive ingredient in marijuana (the chemical that gets a user high). Legal marijuana has a much larger amount of THC (between 15%-30%).

Benefits of industrial hemp

The benefits associated with hemp are endless. Countless products used by people every day can be created from hemp. Some of these products include the following:

• Paper products: Hemp can be used to make paper and it only takes a couple of months to grow. Hemp is environmentally friendly. It is naturally acid free and can be recycled up to 7 times (normal paper can be recycled up to 3 times).
• Clothing: Hemp can be used to make clothing. One acre of hemp produces as much material as 2-3 acres of cotton.
• Building materials: Hemp can be turned into a variety of building materials. You can build a wall out of hemp that is rot free, pest free, mold free, fire resistant, and will last 500 years. You can also make biodegradable plastic out of hemp.
• Gasoline/Fuel: Hemp can be turned into fuel that can be used in your car today. This is done by pressing the hempseed and turning its oil into a biodiesel that is biodegradable and cleaner for the air. Hemp is not the best alternative for fuel because it takes a lot of hemp to make one gallon of gas.
• Nutrition: Hemp can be used as a supplement for nutrition. Hemp is high in protein, contains essential omega 3 & 6 fatty acids, potassium, and dietary fiber.

A $50 billion industry by 2026

The benefits associated with hemp are endless. However, the best part about it is the conditions which it can grow under. If you look at pictures of New York from the mid-1900s, hemp was growing everywhere.

Hemp has multiple growing seasons and it can be grown in some of the toughest environments. Researches have estimated that the Florida hemp industry could be a $460 million dollar industry per year.

0 1613

MCIG Sells Stony Hill Corp. an 80% Stake in its VitaCBD Brand

HENDERSON, NV / ACCESSWIRE / February 27, 2017 / mCig, Inc. (MCIG), a diversified company focused on the cannabis industry, announced today that it has entered into an asset purchase agreement with Stony Hill Corp. (STNY) for the purpose of pursuing mutually beneficial business opportunities in the Cannabidiol (CBD) Industry. Under terms of the agreement, MCIG will sell the VitaCBD brand to STNY, in exchange for total consideration of $850,000 in cash and common stock, and a 20% stake in VitaCBD, LLC, a subsidiary of STNY.

Paul Rosenberg, President and CEO of MCIG, commented, “MCIG has worked diligently to build the VitaCBD product line, but recognizes the need for a strategic partner to assist in branding and marketing of the product. After months of discussions and negotiations, we believe we have found that partner with Stony Hill. We are very bullish on the future revenue potential of VitaCBD and its ability to create value for our company and its shareholders.”

VitaCBD is a highly dedicated group devoted to engineering the purest hemp derived products available. Both hemp and marijuana contain dozens of cannabinoids, naturally occurring chemical compounds, but it is cannabidiol (CBD), in particular, that offers the potential for health and therapeutic benefits without the high. Hemp plants typically contain elevated levels of health-enhancing CBD, but by definition contain only trace levels of THC. This makes the hemp plant attractive to those seeking its potential health benefits as part of an antioxidant-rich lifestyle.

Chris Bridges, President of STNY, stated, “This transaction will expand Stony Hill’s platform of products and accelerate its growth strategy in the industry. Stony Hill and mCig will have a synergistic relationship, combining management and personnel with a dedicated focus on the promotion and deployment of the VitaCBD brand. We are excited to have mCig as a strategic partner and a shareholder in Stony Hill.”

About mCig, Inc.

Headquartered in Henderson, Nevada, mCig Inc. (MCIG) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. MCIG has transitioned from a vaporizer manufacturer to an industry leading, large scale, full service cannabis cultivation construction company, with its Grow Contractors division currently operating in the rapidly expanding Nevada market. The company looks forward to growing its core competencies to service the Ancillary legal Cannabis, Hemp, and CBD markets, with broader expansion to take place once federal laws change. For more information, visit www.mcig.org.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing, and distribution plans and strategies.

Contact:

CEO of mCig, Inc.
Paul Rosenberg
paul@mcig.org

0 2547

Recent research is shedding light on people with the hepatitis C virus (HCV). Doctor Henry Lowe and fellow scientists performed an in vitro study that shows marginal antiviral activity of CBD against HCV. The study combined 10 micrometers of CBD oil with 3 micrometers of HCV and found that CBD stopped the replication of HCV by 86.4%. Surprisingly, this the only in vitro study that has been conducted. Other studies before 2016 lacked the ability to perform tests in controlled test tubes and collected data based on second hand historical information from its participants.

Presently, there is no vaccine for the hepatitis C virus, and HCV is a blood borne virus most common in communities where risk of sharing drug injection equipment is high. The virus can also be transmitted through poor sterilization of medical equipment in hospital settings or through sexual contact. HCV causes liver failure, cirrhosis, and cancer in most cases. According to the World Health Organization, (WHO) between 130-150 million people globally have chronic HCV and approximately 700,000 people die each year from hepatitis C-related liver diseases. Antiviral medication can treat approximately 90% of persons with hepatitis C infection, thereby decreasing the risk of death from liver cancer and cirrhosis, but access to diagnosis and treatment is low.

Dr. Lowe recently stated, “This new discovery, which has fantastic potential for the future, is especially crucial for people in developing countries, because there is a drug which was developed for hepatitis C treatment, but it’s over $85,000 per treatment and very few people in the developing world can afford this. So it is very important that we find less expensive means of treatment, and that is why this discovery and its potential to manage this disease is so important.”

The Eastern European and Central Asian regions are home to an estimated one-quarter of all people who inject drugs worldwide. Because these areas are comprised of developing countries, the manufacturing, distribution and administration of CBD treatment would be a major economic concern to patients. In the United States, CBD oil can run anywhere between $10 to thousands of dollars. For patients in developing countries who use water bottles for light bulbs, this is definitely not ideal.

Mapping out the process from Dr. Lowe’s study to the actual treatment of patients does not seem very promising. It would have to be approved by the World Health Assembly (WHA), which is the board of directors and the supreme decision-making body for the WHO. Comprised of delegates from 192 member states and 62 different countries, its main function is to determine the policies of the Organization. All 192 members would have to be in agreement to allow CBD treatment to be dispersed through various countries.

4 9671

By Jason Spatafora @WolfofWeedSt

“I fear the Greeks, even those bearing gifts.”- Virgil

The DEA’s recent cannabis research expansion is a Harry Houdini inspired smoke show of misdirection all to set up the next trick; there I said it. While some view it as a positive first step, I tend to think it served a very deliberate function. Optically it played directly into expected vitriolic fallout from advocates, activists and media touts, all of which lined up to ignite their “DEA should reschedule cannabis” torches. In a “perfect world” scenario these people aren’t wrong, cannabis isn’t Heroin’s equal & 1+1=2, but just as fire cannot exist in a vacuum, neither can a rational cannabis debate. And while everyone on the side of reason is shouting in unison about rescheduling they failed to see that they might have just had their pockets picked. DEA’s policy statement that everyone seemed to ignore there are 33 words that have the potential to create the legal framework for the monopolization of Cannabis by means of an exclusionary application process.

Prologue – August 10th, 2016

Russ Baer, a staff coordinator for the Drug Enforcement Administration (DEA) media affairs wing gave a response to Steven Nelson of USNEWS.com via email. Nelson later shared a screen grab of the email via tweet. The statement made to him from this Drug Enforcement Administration staff coordinator read:

“Tomorrow morning (August 11th, 2016) the Drug Enforcement Administration will be making some important announcement regarding Marijuana related topics that will be published in the Federal Register. Because of your interest and/or prior engagement with the DEA on this subject, the DEA office of National Media Affairs is reaching out to you regarding these anticipated announcements.”

Over the next 24 hours social media was a blaze, with many people within the industry uncovering the fact that Rescheduling wouldn’t happen and that the DEA response would have to do with research. As expected, the incendiary scheduling of cannabis debate raged on into the following day.

August 11th, 2016

As expected, the Drug Enforcement Administration disappointed the advocates and activists of medical marijuana by not removing or rescheduling marijuana from its class 1 controlled substance status. Yet the DEA, in all of its benevolence, offered a consolation prize of sorts, by “deciding” to expand the study of Medical Marijuana for researchers, Universities & drug companies outside of the confines of a single federally legal facility. The facility, to refresh your memory is located at the University of Mississippi, (ranked 164th in Bio Sciences) and had up to this point been the sole research monopoly on legally grown marijuana, courtesy of the NIDA (National Institute on Drug Abuse).

DEA’s Misdirection Strategy

Over the next few days it seemed that every headline following the DEA’s deliberation was about the archaic rescheduling system & how cannabis is safer statistically than opiates that are schedule 2. Some media outlets went as far as to paint a “glass half full” picture. The LA Times for example did a piece titled “DEA ends its monopoly on marijuana growing for medical research.” The social reaction from cannabis enthusiasts, advocates and potrepreneurs from Main Street to Wall Street was as expected with everyone chiming in on social media to wag their fingers at the DEA. Representative Barbara Lee, a congresswoman from Oakland California stating via tweet “Politicians aren’t doctors or scientists. Marijuana research prohibitions are outdated, unscientific, & dangerous for those who need #MMJ.” As expected the rhetoric from the cannabis side was “The DEA is bad, the War on Drugs is a complete failure, Big Pharma is to blame,” so on and so forth.

IMG_8473

The people aren’t wrong on many of these points. The War in Drugs is a failure when considering addiction has been plateauing since its 1970 inception and US drug control spending is up 2000%, which to date stands at $1.5 trillion dollars. We can go on and on as to where that money went, what industries it created (prison industrial complex), the people it disproportionately targeted (minorities), but that’s a whole other article or book for that matter. Big Pharma however does have its trillion dollars hands in this story, but more on that later as I’ve digressed.

Not to go back and pick on the LA Times click-bate headline of “DEA ends its monopoly on marijuana growing for medical research,” but did it really end the monopoly? Let’s evaluate the idea. Yes, a monopoly is defined as “the exclusive possession or control of the supply or trade in a commodity or service.” The University of Mississippi was in fact in exclusive possession of the NIDA edict to legally grow marijuana and study it. On the surface the Monopoly has ended, but the reality is that we are just switching out the term Monopoly for an Oligarchy. Is an oligarchy any different than a monopoly in the sense that it’s just a smaller group carving out the biggest slices for themselves, eliminating competition by means of out maneuvering or outspending their opponent in an effort to influence policy such as this? Consider that the biggest lobby against the cannabis Industry is the pharmaceutical industry, yet they’re simultaneously studying cannabis for the purpose of synthesizing its many chemical compounds to create their high margin drugs.

Currently, their high margin bread and butter are the opioids for pain management such as OxyContin, Percocet and their generic versions of each. The drug companies are experts at isolating molecules from nature to create drugs that cost pennies to manufactures. In a zero sum game, cannabis is a direct threat to pharma companies, by snatching billions in profit and simultaneously causing billions in losses. Anti-cannabis lobbies would also be at risk as the pharmaceutical giants that feed them down on K Street would lose out on easy paydays. These anti-Marijuana lobbyists provide a micro look at the systemic problems within American politics illustrating how/why elected officials in Congress consistently vote against the interests of their collective constituency and bring forth carefully crafted bills or amendments like this one.

On the DEA’s policy statement and legal considerations section, under, legal applicable considerations it states.

“Second, as with any application submitted pursuant to section 823(a), in determining whether the proposed registrationwould be consistent with the public interest, among the factorsto be considered are whether the applicant has previous experience handling controlled substances in a lawful manner and whether the applicant has engaged in illegal activity involving controlled substances. In this context, illegal activity includes any activity in violation of the CSA (regardless of whether such activity is permissible under State law) as well as activity in violation of State or local law. While past illegal conduct involving controlled substances does not automatically disqualify an applicant, it may weigh heavily against granting the registration.”

Translation, grow marijuana even in a state where it’s legal and you are going to have a hard time becoming a manufacturer or researcher for the DEA’s new policy, thus excluding tier one cultivators in practice and likely creating a perpetual home for cannabis on the scheduling list. Prohibition’s end could very well be right around the corner, but the fear is in the form of legal medical marijuana at a Walgreens near you. I asked the DEA’s Russ Baer directly if the inserted language above in bold would be a non-starter for current cultivators wanting to become manufacturers as they are in clear Violation of CSA? In a written statement to Marijuana Stocks the DEA’s official response was:

“DEA is serious about facilitating marijuana research and that there is a lawful pathway for doing so. This DEA decision will facilitate increased research involving marijuana, within the framework of the law and U.S. treaty obligations, to enhance the drug’s supply available to researchers. The goal of this historic and monumental policy shift is to increase the amount and variety of marijuana available to researchers and make it easier for researchers to obtain marijuana as compared to current system under which marijuana must be obtained from NIDA. Growers must become registered with DEA, following the submission of an application, which DEA will evaluate in accordance with the CSA. Registered growers will need to comply with all CSA regulatory requirements, such as quotas, record keeping, order forms, and maintenance of control against diversion. Marijuana produced under this proposal may only be supplied to DEA-registered manufacturers and researchers, and only for purposes authorized by the CSA.

All potential new drugs, including drug products made from marijuana, are subject to the rigors of the drug approval process mandated by the Federal Food, Drug and Cosmetic Act (FDCA). This drug approval process requires that before a new drug is allowed to enter the U.S. market, it must be demonstrated through sound clinical trials to be both safe and effective for its intended uses,” stated Russ Baer of the Drug Enforcement Agency.

When asked if the inserted language also creates an unfair advantage for Pharma companies the response from the Drug Enforcement Administration circled back to the CSA (Controlled Substance Act) stating that the “DEA has adopted a new policy, consistent with the CSA and U.S. treaty obligations, under which additional entities may become registered with DEA to grow and distribute marijuana for research purposes. DEA will evaluate each application it receives to determine whether adding such applicant to the list of registered growers is necessary to provide an adequate and uninterrupted supply of marijuana to researchers in the U.S. In addition, applicants must demonstrate their ability to safely secure the drugs to prevent diversion, while abiding by the approved research protocol.”

The Controlled Substance Act

Everything points back to the Controlled Substance Act, a bill that was introduced into the Congress by Harley Staggers and took less than 6 weeks to get passed by the Senate and signed into law by President Richard M. Nixon. The signing of this document not only created the “War on Drugs,” but put an enforcement agency (DEA) in charge of Cannabis scheduling, circumventing the FDA in a move that creates an inter-agency firewall of sorts. The DEA’s position on why the FDA, who already regulates pharmaceutical drugs, isn’t in charge of marijuana rescheduling was point blank, “The Controlled Substances Act provides a mechanism for substances to be controlled (added to or transferred between schedules) or decontrolled (removed from control). The CSA provides roles for DEA and the FDA. Proceedings to add, delete, or change the schedule of a drug or other substance may be initiated by DEA, HHS, or by petition from any interested party. Once initiated, the process involves a deliberate and collaborative interagency exchange.”

IMG_8472

In Laymen’s terms CSA effectively says “DEA you’re in charge of this, FDA you’re in charge of that.” Unfortunately, Marijuana will never be completely removed from the scheduling list unless there is a major political overhaul in every branch of government, if and only if elected officials stop letting lobbies pour honey in their ears and money into campaigns. The reality from my perspective is that the DEA is a scapegoat, the perfect Boogey Man, simply because their job is to follow orders. They are soldiers in a sense, adhering to the guidelines of the Controlled Substance Act (CSA), a legal document crafted by a congress, molded in the image of benefactors, used to fuel a fake war and create cottage industries.

The DEA knows marijuana is safer than Oxy and that’s not speculation that’s a direct quote. They don’t want to go after the mother transporting medication to her sick child because they’re suffering from seizures. They want the dangerous individuals like El Chapo or the pill mills slinging Oxy off the streets. They have no interest in going after all cultivators following state law to the letter. Are there exceptions, of course! Does it make these comments directly from them any less true? No.
DEA’s direct position on which drug is more dangerous from a consumption standpoint as it relates to Cannabis vs OxyContin? “There were more than 47,000 drug overdose deaths in 2014, or approximately 129 per day, more than half (61 percent) of which involved either a prescription opioid or heroin. Marijuana meets the statuary criteria of a Scheduled I controlled substance, and has been determined to have a high abuse potential with no currently accepted medical use. Schedule I includes some substances that are exceptionally dangerous (including heroin and LSD) and some that are less dangerous (including marijuana, which is less dangerous than some substances in other schedules).” When asked point blank, what’s more dangerous Oxy or Marijuana DEA says “Oxy.”

Robert Capecchi, Director of Federal Lobbying at the Marijuana Policy views medical marijuana legalization as a means to an opioid end as well as fiscal no brainer with far reaching benefits.

“Ending marijuana prohibition will allow licensed businesses to cultivate, distribute, and sell marijuana to adults. Unlike the criminal market, a legal and regulated market means products are pure, tested and labeled, sales are taxed, and business disputes are resolved in the courts, not with violence. Additionally, there is promising evidence to suggest that legal access to medical marijuana reduces the rates of opioid overdoses and the reliance on prescription pain killers.”

Foregone Conclusion?

Prohibition’s end could very well be right around the corner, but would we want it in the form of legal medical marijuana at a Walgreens near you? August 11th’s ruling was either one of many dominos in the quest for the monopolization of cannabis or just a pessimistic idea based off of history repeating itself. Regardless of which reality we are presently in, it doesn’t hurt to try and connect the dots, but if I can leave you with one last thing it’s the number 6630507. In case you’re wondering that’s the United States patent # they filed for cannabis in 2003 citing “multiple therapeutic uses.” I can only postulate why they did that….

Regards,

Jason Spatafora

Drug War

0 5113

@WolfOfWeedST

With the Trump Administration in complete disarray and touting debunked information about Cannabis & Opioid connections we at MarijuanaStocks.com decided to play a little game of devils advocate. The fact remains that the Trudeau administration remains progressive and is doing what all governments should be doing i.e. listening to its people. Canadians are in overwhelming support of legal cannabis markets which is why they legalized medical marijuana last year. This year the country plans on legalizing recreational use in an effort to crush black markets, create jobs, industry and position itself as a worldwide leader in cultivation. With a completely legal market Canada will face one major issue that will reap major benefits to public cultivation companies. That issue being one of supply and demand. Already operating at a deficit and coupled with an approval process by Health Canada that can take years we foresee investors sending their capital north of the border unless they are invested in companies insulated by restrictions on the recreational markets. Those US companies being: Construction for Cultivation, manufacturers of products, companies monetizing industrial Hemp’s many uses, CBD manufacturers, technology & media services (like us).

One of the highly anticipated events of 2017 is the tabling of legislation as it relates to a legal recreational cannabis program in Canada. This development is expected to take place in the Spring.

During December, a federal task force released its long-awaited recommendations relating to the legalization of recreational marijuana. The report was prepared by a committee comprised of nine members who have worked together since June.

All Eyes on Legislation this Spring

When Canada legalizes recreational marijuana, demand is going to increase significantly, however it will take time for the program to be up and running. For this reason, Canadian licensed medical cannabis producers have been aggressively raising capital to make acquisitions and to increase production capacity.

One of the largest fundamental changes within the Canadian cannabis sector over the last year relates to the amount of capital entering the industry as well as the source of the capital. The capital entering the industry is not only larger but smarter too; these investors and firms are long-term holders that see the bigger picture.

Five Opportunities to Watch

The Canadian cannabis industry has continued to be a bright spot for cannabis investors and 2017 has already provided investors with strong investment returns.

This sub-sector of the cannabis industry has been on fire since July 2016 and the increased interest has been fueled by anticipation of Canada becoming the first G-7 nation to legalize recreational cannabis.

Although the Canadian cannabis industry offers investors a lot of opportunity, it does not come without risk. Many of the companies levered to this sector have seen a significant rally over the last six months while some have not fared as well.

We want highlight five Canadian cannabis stocks that should be on every investors radar. From

The Green Organic Dutchman’s second round of financing closes today at 5pm and investors can still reach out to support@sbpartners.io if they still want to access this opportunity.

Terms of the offering are as follows: The company is selling units at $1.15 CAD per unit and the minimum purchase level is 5,000 units. Each unit consists of one common share and one full share purchase warrant. Each warrant provides the investor to purchase shares of The Green Organic Dutchman at $2.15 for the next two-years no matter what price the shares are trading at.

The Green Organic Dutchman produces farm grown pharmaceutical grade organic cannabis. The company has differentiated itself from the competition by producing high-quality organic cannabis that sells for a higher price and has better profit margins. The company is led by a management team that has a proven track record of success with licensed Canadian medical cannabis producers such as OrganiGram and Emblem Corp.

Aphria (APH.V: TSX Venture) (APHQF: OTC) has been one of the top performers this year and the shares are up approximately 30% YTD. The shares moved considerably higher after the company received conditional approval to up-list on the TSX exchange and we remain favorable on the company’ long-term outlook.

In early February, Aphria announced a $50 million private placement at $5.00 a share and this transaction is expected to close this week. The company expects that 80% of the net proceeds will be allocated towards the currently unfunded portion of Part IV Expansion, with the balance being allocated towards strategic investments.

The Part IV expansion will increase Aphria’s capacity from 300,000 to 1 million square feet. In addition, the company’s infrastructure will grow to over 250,000 square feet which is necessary to service the expected 70,000 kilograms of eventual annualized harvests. The project includes 700,000 square feet of Dutch style greenhouses, 230,000 square feet of infrastructure, including new Level 9 vaults, automation for all the greenhouses, processing areas, warehouse facilities, a 15 MW power and heat co-generation facility and security consistent with ACMPR standards.

Aphria anticipates completion of Part IV within 12 months, Health Canada approvals within 4 months of completing the expansion and first harvest within 4 months after such approvals.

In December 2016, Aphria invested $8.4 million in Canabo Medical Inc. (CMM.V: TSX Venture) (CAMDF: OTC) at $1.40 a share. Canabo is another stock we are very favorable as the shares trade at an almost 40% discount to the level at which Aphria invested at.

Canabo owns and operates the largest line of medical cannabis clinics in Canada and we expect to see the company continue to expand its footprint across Canada.

CMM.V is trading at $0.85 after the shares rallied more than 13% on above-average volume. We highlighted the company last month as an attractive opportunity and continue to see upside to current levels. The company’s United States symbol, CAMDF is trading below $0.67 after a 16.4% rally and we continue to see upside to these levels.

PharmaCan Capital (MJN: TSX Venture) (PRMCF: OTC) has the top performing licensed Canadian medical cannabis producer this year and the shares are up 92.6% YTD. The company does business as Cronos Group and in 2016, it sold one of its properties to NYSE-traded Innovative Industrial Properties (IIPR).

The shares were under pressure last week after the company announced a $15 million private placement at $2.25 a share. MJN.V quickly bounced back and rallied more than 40% over the few trading days.

The company’s wholly-owned subsidiary, In The Zone, recently received approval from Health Canada to sell medical cannabis. This comes while its other wholly-owned subsidiary, Peace Naturals is positioned to capitalize on the recent medical cannabis legislation in Germany through its export relationship with Pedanios GmbH.

Although the shares have recent run significantly higher, we have become increasingly favorable on the company over the last quarter and continue to monitor trading closely. Become a Technical420 Premium Member to keep up with our analysis.

Canopy Growth Corp. (WEED.TO: TSX) (TWMJF: OTC) continues to be the Canadian medical cannabis leader and we view the company as one of the best long-term cannabis investments.

The company recently completely the acquisition of Mettrum Health, which significant expanded its product line and led to a surge in revenue. The market did not initially respond favorable to Canopy earnings report and the shares recorded its largest drop of the year.

During the quarter, Canopy Growth recorded $3 million in net income off $9.8 million in revenue and total revenue increased 15% when compared to the prior quarter and 180% when compared to the same period last year.

During the quarter, the company sold 1,245 kilograms and kilogram equivalents at an average price of $7.36 per gram, up from 462 kilograms at an average price of $7.34 per gram during the prior year period.

The company recorded strong growth on pretty much all metrics and as of December 31st , Canopy Growth reported to have over 29,000 registered patients which is more than 260% higher than the number of patients as of December 31, 2015.

Canopy has recaptured most of its losses and we continue to remain favorable and monitor trading activity closely. WEED.TO recently traded into the $13.20 range and the shares are currently trading at $12.64. We remain favorable on Canopy Growth and this company should be on every cannabis investor radar screen.

0 1589

At the age of 19, Amy Black, the former Morgan Academy student’s, life was thrown into disarray when she was diagnosed with sarcoidosis. The condition affects one in every 10,000 people in the United Kingdom. It causes small patches of swollen and red tissue, called granulomas, to develop in the organs of the body. It usually affects the skin and the lungs. There is no cure for the disorder. Amy, now 23, is currently taking gabapentin, co-codamol, and amitriptyline but said the drugs have terrible side effects. She is currently taking cannabis oil in her efforts to live a “normal life.” Now she has spoken out in support of cannabis oil and called for the drug to be made available free on the NHS.

Amy said, “I feel this is the first step to getting my life back to the way it was before diagnosis and I was told I’d never feel that way ever again by doctors. My family has seen an incredible transformation in me and I believe there is a strong case for this to be medically regulated. From being a fit and healthy teenager I became too unwell to get out of bed was a major shock. Since I’ve started taking these capsules, I feel my life is no longer dictated by sarcoidosis.” Those supporting the oil believe the ingredient CBD offers considerable health benefits. Cannabis oil is very low in the psychoactive substance THC, which means that the use of the oil does not create a “high.” Therefore, it does not fall within the drug classification categories for illegal substances.

Amy has been using the oil capsules since December and said she has seen a reduction in her sickness, migraines, and tremors. When she first became ill, she thought she had experienced an allergic reaction to a tattoo when a rash appeared on her skin. Amy was shocked when doctors diagnosed her with sarcoidosis. The condition causes painful symptoms, including: temporary blindness, crippling migraines, and tremors. Amy stated, “I’ve had days where I can’t get out of bed from the pain. I lose sight in my left eye, I get crippling migraines, wake up in the night with horrible nerve pain, have regular tremors, difficulty breathing, and get raised rashes on my skin. I’ve been in and out of hospital for the past four years and been close to heart attacks and seizures, with my body attacking itself. I’m taking tablets daily but they have horrible side effects.”

The beauty therapy student was researching alternative medicines to treat her illness and was recommended cannabis oil. She said the capsules make her feel “normal again.” She continued, “I discussed the option of herbal alternatives with the doctors who were against me using it. But having spoken with others I was recommended CBD capsules. I was told people facing long-term diseases were able to stop using other medicines. I’ve been taking the capsules since December and I’ve had no pains, no migraines, no tremors, no sickness, nothing.”

CBD oil is the concentrated, distilled form of the plant most commonly known as marijuana. Brands marketed for medical use typically contain CBD, which proponents claim can help people experiencing a wide range of conditions, including: PTSD, arthritis, alcoholism, diabetes, multiple sclerosis, chronic pain, and schizophrenia. CBD does not make people feel “stoned.” It is now possible to buy CBD oils and ready-to-use vaporizer pens from a growing number of websites in the UK. Any product containing CBD alone is not illegal. THC, another cannabinoid, has a psychoactive effect and is the mind-altering substance found in cannabis. If sellers offer products which contain THC they could find themselves in trouble.

Researchers first looked at the anti-cancer properties of cannabinoids back in the 1970s, and hundreds of scientific studies have been published since then. Some research supports the claim that cannabinoids can reduce chemotherapy-related pain, nausea, and vomiting in patients. Other studies have shown cannabinoids can uniquely target and kill cancer cells. However, investigation into the health benefits of cannabinoids is still in the early stages. Hundreds of researchers around the world are investigating their potential in treating cancer and other diseases brought together under the blanket organisation, The International Cannabinoid Research Society. A Scottish Government spokesman said, “While the treatment and prevention of drug problems are devolved to the Scottish Government, policy on the use of controlled drugs is currently reserved to the UK Government. All medicinal products must be fully tested and researched before they can be licensed for use in the UK, and the licensing, safety and efficacy of medicines is also currently reserved to the UK Government.”

0 1580

It seems people are searching for peace, tranquility, and a sense of overall well being these days. There is so much anxiety in combination with the instability of the the economy, government, the weather, and life in general is overwhelming for many of us. The pursuit is always to find that natural high, whether from yoga, meditation, running, or anything that gets the blood moving and oxygen flowing.

Getting high on life can be a wonderful experience. For many, the high is achieved through the use of psychoactive substances. Ever since the 2016 election, there is a lot of hype going around the states that have passed the use of cannabis, since the legalization of it is becoming more broad. Among the cannabinoids in marijuana, the main psychoactive compound, THC, often transcends the other one. Cannabidiol can provide a natural anti-anxiety, antipsychotic, and anti-epileptic effect.

Cannabidiol, or CBD, is used by itself, with no high. However, when combined with THC, the relaxing effect is claimed to fight off any feelings of paranoia that can sometimes be felt under the influence. There are a few digital gateways that “explore the evolving world of cannabis products and services” with a target on marijuana culture. Many others are cropping up for consumers seeking more in-depth information pertaining to the rapidly growing recreational and medical marijuana industry.

Smoking is the most popular way to ingest the substance and offers the fastest reaction. Vaporizing (vaping) has become more popular since a vaporizer creates vapor, there is a reduced risk of choking on the drug upon inhaling. It offers a smoother delivery. The most attractive and pleasing for many are the edibles, or “Medibles.” The creative delivery of cannabis-infused food and beverages claim to provide a longer lasting effect.

0 2688
cbd stocks

In Wisconsin, the subject of cannabis for medicinal purposes has been nearly untouched aside from a 2014 proposal that exempted patients with seizure afflictions and a doctor’s recommendation from arrest for possessing or using CBD oil. That proposal didn’t do much to help patients with seizures and nothing to help the many other patients who would benefit from medical cannabis. This year they are making another attempt at passing a CBD proposal that would legalize the use and possession cannabidiol for patients with a doctor’s prescription.

A similar proposal was introduced last year in the Assembly and passed, however, it never made it out of the Senate. This proposal was introduced in the Senate and was approved with a 31-1 vote, with the lone opponent Duey Stroebel, a Republican Senator. While this proposal will open up access to non-psychoactive CBD oil to patients beyond those with seizure disorders, many find that marijuana products with both THC and CBD are more beneficial for most disorders. This means that those this law will help are still greatly limited in comparison to patients in other medical cannabis states.

Sen. Chris Larson, D-Milwaukee, one of the bill’s co-sponsors stated, “If we had done this when the debate first started, it would have cut out four years of suffering for those kids, four years of anguish for those parents.” While it’s likely that this proposal will pass in the Assembly, considering a similar measure made it through last year, there are still too many flaws in the way it’s written. Not only do CBD-only laws limit the number of suffering patients that can legally benefit from medical cannabis, but many don’t create a legal way for patients to access this medicine once a doctor approves it for them in a prescription.

This proposal would not create in-state production or sale of CBD oil, so no matter how patients or caregivers go about it, they are still taking a legal risk just to obtain their medicine. However, while this bill does not go as far as it really needs to, it is at the very least a start. It will give many parents and patients the comfort of knowing at least part of the risk in using their preferred method of treatment has been taken away.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements